SEC Filing Document

Company: BIOVENTRIX, INC.
Ticker: 
CIK: 1283259
Filing Type: S-1/A
Document Type: S-1/A
Date Filed: 2026-05-15
Accession Number: 0001493152-26-023752
Exchange: 
SIC Code: 3841
SIC Description: Surgical & Medical Instruments & Apparatus
URL: https://www.sec.gov/Archives/edgar/data/1283259/000149315226023752/forms-1a.htm

Chunk 24 of 94
Word Count: 1365
Character Count: 8868

Document Content:

that can affect the validity of patents issued under previous legal standards. The U.S. Patent and Trademark Office, or USPTO, and various foreign governmental patent agencies further require compliance with a number of procedural, documentary, fee payments (e.g., maintenance and annuity fee payments), and other provisions during the patent procurement process as well as over the life span of an issued patent. Noncompliance can result in abandonment or lapse of a patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. In such an event, competitors might be able to enter the market or compete more directly at an earlier time than would otherwise have been the case. may incur substantial costs as a result of litigation or other proceedings relating to patent and other intellectual property rights and we may be unable to protect our rights to, or use of, our technology.

Our
commercial success depends in part on our ability to operate without infringing the intellectual property and proprietary rights of third
parties. Our business, product candidates, and methods could infringe the patents or other intellectual property rights of third parties.
Our competitors may seek, or may already have obtained, patents that will limit, interfere with, or eliminate our ability to make, use,
sell, offer to sell, and license our product candidates and technologies either in the United States or in international markets. It
may be difficult or impossible to identify, prior to receipt of notice from a third party, the patents, trade secrets, or other intellectual
property rights of a third party, either in the United States or in foreign jurisdictions, that relate to our business, product candidates,
and methods. We have not conducted an extensive search of patents issued or assigned to other parties, including our competitors, and
no assurance can be given that patents containing claims covering our product candidates, parts of our product candidates, technology
or methods do not exist, have not been filed or could not be filed or issued. In addition, because patent applications can take many
years to issue and because publication schedules for pending applications vary by jurisdiction, there may be applications now pending
of which we are unaware and which may result in issued patents which our current or future product candidates infringe. Also, because
the claims of published patent applications can change between publication and patent grant, there may be published patent applications
that may ultimately issue with claims that we infringe.

Our
industry is characterized by frequent and extensive litigation regarding patents and other intellectual property rights. Many companies
in our industry with substantially greater resources than us have employed intellectual property litigation as a way to gain a competitive
advantage. We may become involved in litigations, interference proceedings, derivation proceedings, inter partes review proceedings,
oppositions, reexaminations, protests or other potentially adverse intellectual property proceedings as a result of alleged infringement
by us of the rights of others, or as a result of priority of invention disputes or ownership disputes with third parties, either in the
United States or internationally. In those proceedings, Third parties may challenge the validity and enforceability of any of our issued
patents, and whether we own those patents. Even if we believe such claims are without merit, there is no assurance that a court would
find in our favor on questions of infringement, validity, enforceability or priority. A court of competent jurisdiction could hold that
these third-party patents are valid, enforceable and infringed by our product candidates. In order to successfully challenge the validity
of any such U.S. patent in federal court, we would need to overcome a presumption of validity. As this burden is a high one requiring
us to present clear and convincing evidence as to the invalidity of any such U.S. patent claim, there is no assurance that a court of
competent jurisdiction would invalidate the claims of any such U.S. patent. If we are found to infringe third-party patents, and we are
unsuccessful in demonstrating that such patents are invalid or unenforceable, such third parties may be able to block our ability to
commercialize the applicable product candidates or technology unless we obtain a license under the applicable patents, or until such
patents expire or are finally determined to be held invalid or unenforceable. Such a license may not be available on commercially reasonable
terms, or at all. Even if we are able to obtain a license, the license would likely obligate us to pay significant license fees and/or
royalties, and the rights granted to us might be non-exclusive, which could result in our competitors gaining access to the same technology.
If we are unable to obtain a necessary license to a third-party patent on commercially reasonable terms, or at all, we may be unable
to commercialize our product candidates, or such commercialization efforts may be significantly delayed, which could in turn significantly
harm our business.

Claims
against us relating to the infringement of third-party proprietary rights or proprietary determinations, even if not meritorious, could
result in costly litigation, lengthy governmental proceedings, diversion of our management’s attention and resources, or entrance
into royalty or license agreements that are not advantageous to us. In any of these circumstances, we may need to spend significant amounts
of money, time and effort defending our position. Some of our competitors may be able to sustain the costs of complex patent litigation
more effectively than we can because they have substantially greater resources. In addition, any uncertainties resulting from the initiation
and continuation of any litigation could have a material adverse effect on our ability to raise the funds necessary to continue our operations.
Even if we are successful in these proceedings, we may incur substantial costs and divert management time and attention in pursuing these
proceedings, which could have a material and adverse effect on us. If we are unable to avoid infringing the intellectual property rights
of others, we may be required to seek a license, defend an infringement action, challenge the validity of intellectual property in court,
redesign our product candidates, product candidates, or methods, or cease production of our product candidates altogether.

Competitors
may also infringe our patents. If we file an infringement proceeding to enforce one or more of our patents, a court may decide that patents
owned by us are invalid or unenforceable, or may refuse to enjoin the other party from using the technology at issue on the grounds that
our patents do not cover such technology. An adverse result in any litigation proceeding could put one or more of our patents at risk
of being invalidated or interpreted narrowly. Furthermore, because of the substantial amount of discovery required in connection with
intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during
litigation. Even if resolved in our favor, litigation or other legal proceedings relating to intellectual property claims may cause us
to incur significant expenses and could distract our management and other personnel from their normal responsibilities. In addition,
there could be public announcements of the results of hearings, motions or other interim proceedings or developments, and if securities
analysts or investors perceive these results to be negative, it could have a substantial adverse effect on our common stock price. Such
litigation or proceedings could substantially increase our operating losses and reduce the resources available for development activities
or any future sales, marketing or distribution activities. We may not have sufficient financial or other resources to conduct such litigation
or proceedings adequately. Some of our competitors may be able to sustain the costs of such litigation or proceedings more effectively
than we can because of their greater financial resources and more mature and developed intellectual property portfolios. Uncertainties
resulting from the initiation and continuation of patent litigation or other proceedings could have a material adverse effect on our
ability to compete in the marketplace. Any of the foregoing could have a material adverse effect on our business, financial condition
or results of operations.

our trademarks and trade names are not adequately protected, then we may not be able to build name recognition in our markets of interest
and our business may be adversely affected.